Drug intelligence / Profile preview

mitometh

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

Mitometh is a methylated homolog of mitotane, developed as an adrenalytic agent. It was studied for the treatment of adrenal cancer due to its structural similarity to mitotane, which is used in adrenocortical carcinoma. However, preclinical and clinical studies indicated that Mitometh did not demonstrate efficacy in treating adrenal cancer. Its mechanism involves targeting the adrenal cortex, but it failed to show significant therapeutic benefit in animal models and human cell lines[3].

Targets

ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on mitometh.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitometh.

Explore the full profile